- Trials with a EudraCT protocol (34)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
34 result(s) found for: Breast Self Examination.
Displaying page 1 of 2.
EudraCT Number: 2019-002635-28 | Sponsor Protocol Number: 69081 | Start Date*: 2019-10-14 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: The effect of hyperbaric oxygen therapy on breast cancer patients with late radiation toxicity | ||
Medical condition: Late radiation toxicity | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000458-24 | Sponsor Protocol Number: BREASTECT | Start Date*: 2021-05-20 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE | |||||||||||||
Full Title: Pilot study on electrochemotherapy in metastatic breast cancer (BREAST ECT) | |||||||||||||
Medical condition: Metastatic breast cancer during systemic therapy and in disease stability according to RECIST 1.1 criteria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002323-38 | Sponsor Protocol Number: GBG105GeparPiPPa | Start Date*: 2022-08-29 |
Sponsor Name:German Breast Group | ||
Full Title: A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-pos... | ||
Medical condition: Patients with early breast cancer | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005575-12 | Sponsor Protocol Number: BYON5667.002 | Start Date*: 2021-06-30 | ||||||||||||||||
Sponsor Name:Byondis B.V. | ||||||||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled trial with a single arm run-in period to evaluate the safety and efficacy of sodium thiosulfate (BYON5667) eye drops to reduce ocular tox... | ||||||||||||||||||
Medical condition: Single arm run-in period: Patients with solid tumours (excluding gastric tumours and adenocarcinomas of the gastroesophageal junction) Randomized part of the study: patients with locally advanced ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) BE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001161-16 | Sponsor Protocol Number: ML28879 | Start Date*: 2013-09-12 |
Sponsor Name:ROCHE SPA | ||
Full Title: NATIONAL PHASE IIIB PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, OPEN LABEL STUDY TO ASSESS THE SAFETY OF SUBCUTANEOUS TRASTUZUMAB AND MOLECULAR BIOMARKERS IN PATIENTS WITH EARLY AND LOCAL... | ||
Medical condition: EARLY AND LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000158-36 | Sponsor Protocol Number: OXYPEP202 | Start Date*: 2016-03-18 | |||||||||||
Sponsor Name:PEPTONIC medical AB | |||||||||||||
Full Title: A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy | |||||||||||||
Medical condition: Vaginal Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003395-13 | Sponsor Protocol Number: KOA-21-02 | Start Date*: 2022-03-03 | |||||||||||
Sponsor Name:Bioventus LLC | |||||||||||||
Full Title: A Multiple Arm, Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particu... | |||||||||||||
Medical condition: Osteoarthritis of the knee | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001027-40 | Sponsor Protocol Number: ERIBRAIN-IPC2017-014 | Start Date*: 2018-09-11 | |||||||||||
Sponsor Name:Institut Paoli-Calmettes | |||||||||||||
Full Title: ERIBRAIN - A phase II study of Eribulin in brain metastases from HER2-negative breast cancer pre-treated with anthracyclines and taxanes | |||||||||||||
Medical condition: HER2-negative breast cancer with brain metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003835-18 | Sponsor Protocol Number: GE-135-004 | Start Date*: 2009-04-21 |
Sponsor Name:GE Healthcare Ltd | ||
Full Title: A phase 2, open-label test-retest study to assess the reproducibility of quantitative measurements of 18F uptake by solid tumours using PET imaging following intravenous administration of AH111585 ... | ||
Medical condition: Adult subjects with solid primary or metastatic tumours 2 cm or more in diameter. Malignancies may include but are not limited to non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), gl... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004010-17 | Sponsor Protocol Number: ANG206 | Start Date*: 2004-12-09 |
Sponsor Name:Amersham plc and its Amersham Health affiliates, trading as GE Healthcare | ||
Full Title: An open-label, multi-centre, phase 2a study to assess the feasibility and safety of intravenous bolus administration of 99mTc-NC100692 Injection in imaging metastases in late stage cancer patients. | ||
Medical condition: The subjects to be included in this study have been diagnosed with primary breast, lung (non-small cell), ovarian or prostate cancer or malignant melanoma and have metastatic spread of the cancer t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) GB (Completed) DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000382-32 | Sponsor Protocol Number: REP0121 | Start Date*: 2021-08-16 | |||||||||||
Sponsor Name:Dompé farmaceutici s.p.a. | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled phase 2 study to assess the efficacy and safety of oral reparixin in cancer related fatigue in patients with locally advanced or metastat... | |||||||||||||
Medical condition: Cancer related fatigue in patients with locally advanced or metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004267-40 | Sponsor Protocol Number: MIT-Es0001-C202 | Start Date*: 2017-01-16 | |||||||||||
Sponsor Name:Estetra SPRL | |||||||||||||
Full Title: A SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE OVARIAN FUNCTION INHIBITION OF A MONOPHASIC COMBINED ORAL CONTRACEPTIVE (COC) CONTAINING 15 MG ESTETROL (E4) AND 3 MG DROSPIRE... | |||||||||||||
Medical condition: Hormonal contraception in woman seeking contraception | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004937-15 | Sponsor Protocol Number: BNC210.006 | Start Date*: 2015-04-16 | |||||||||||
Sponsor Name:BIONOMICS LIMITED | |||||||||||||
Full Title: A randomized, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured... | |||||||||||||
Medical condition: Generalized Anxiety Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001289-14 | Sponsor Protocol Number: MIT-Do001-C301 | Start Date*: 2020-02-05 | |||||||||||
Sponsor Name:Estetra SRL | |||||||||||||
Full Title: A Randomized Double-blind Placebo Controlled Phase 3 Trial to evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comf... | |||||||||||||
Medical condition: Moderate to Severe Vasomotor Symptoms (VMS) in Postmenopausal Women | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: PL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) HU (Completed) LT (Ongoing) CZ (Completed) ES (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000402-32 | Sponsor Protocol Number: EU-CCBE-2003 | Start Date*: 2005-06-07 |
Sponsor Name:Genetronics Biomedical Corporation | ||
Full Title: An open-label study using the MedPulser Elektroporation System to treat cutaneous & subcutaneous foci of cancer | ||
Medical condition: Histologically confirmed recurrent SCC, recurrent BCC, Melanoma, Adenocarcinoma (i.e., local recurrence of breast cancer), Merkel Cell Carcinoma, Cutaneous Lymphoma, other subcutaneous solid tumors... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000716-30 | Sponsor Protocol Number: RGL-003-001 | Start Date*: 2020-09-10 | |||||||||||
Sponsor Name:Gedeon Richter Plc. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter, proof-of-concept study to evaluate a combined oral contraceptive (COC) containing 30 µg ethinylestradiol and 150 µg levonorgestrel plus ... | |||||||||||||
Medical condition: Hypoactive sexual desire disorder (HSDD) secondary to combined oral contraception use. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) PL (Completed) CZ (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000829-31 | Sponsor Protocol Number: ML28878 | Start Date*: 2013-10-10 | |||||||||||
Sponsor Name:Roche Nederland B.V. | |||||||||||||
Full Title: A LOCAL, OPEN LABEL, MULTICENTRE, PHASE IIIB STUDY, INVESTIGATING SUBCUTANEOUS TRASTUZUMAB ADMINISTERED AT HOME WITH SINGLE INJECTION DEVICE IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER | |||||||||||||
Medical condition: HER2-positive early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013333-24 | Sponsor Protocol Number: EMR 701048-525 | Start Date*: 2009-08-03 | |||||||||||
Sponsor Name:MERCK SERONO SPA | |||||||||||||
Full Title: Multicenter, open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inje... | |||||||||||||
Medical condition: RELAPSING MULTIPLE SCLEROSIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002078-23 | Sponsor Protocol Number: M06-829 | Start Date*: 2006-10-12 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG (Abbott) | |||||||||||||
Full Title: A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease. | |||||||||||||
Medical condition: Moderate to severe Crohn's Disease (Harvey Bradshaw Index score greater or equal to7). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) NO (Completed) FI (Completed) PT (Completed) SK (Completed) DE (Completed) IE (Completed) DK (Completed) FR (Completed) AT (Completed) GB (Completed) SE (Completed) GR (Completed) CZ (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006199-39 | Sponsor Protocol Number: 310523 | Start Date*: 2007-07-05 | |||||||||||
Sponsor Name:Bayer AB, Bayer Schering Pharma | |||||||||||||
Full Title: A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17b-estradiol [E2] / 0.25 mg drospirenone... | |||||||||||||
Medical condition: Women suffering from postmenopausal symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.